规范甲状腺相关眼病眶周注射糖皮质激素的治疗  

The importance of standardized periorbital steroid injections for thyroid-associated ophthalmopathy

作　　者：李冬梅 姜雪 Li Dongmei;Jiang Xue(Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing Key Laboratory of Ophthalmology&Visual Sciences,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院北京同仁眼科中心,北京市眼科学与视觉科学重点实验室,北京100730

出　　处：《中华眼科杂志》2022年第9期641-645,共5页Chinese Journal of Ophthalmology

基　　金：国家自然科学基金面上项目(82071005)。

摘　　要：甲状腺相关眼病(TAO)已成为发病率首位的成年人眼眶疾病,其发病机制复杂,临床表现多样。TAO治疗方法的研究已取得长足的进步,眶周糖皮质激素注射作为一种局部治疗方式,对眼部体征有一定的改善、不良反应小。但目前国内缺乏规范的眶周注射治疗方案,造成并发症发生的风险增加。因此,规范TAO眶周注射糖皮质激素的治疗具有重要的临床意义。Thyroid-associated ophthalmopathy(TAO)is now the most prevalent orbital disease in adults,with a complex pathophysiology and a wide range of clinical symptoms.In recent years,significant progress has been made in the research on the treatment of TAO.Periorbital steroid injections are considered a precise local treatment and can improve ocular symptoms with minor side effects.However,there is no standardized orbital injection protocol in China,resulting in increased complications.Therefore,it is essential to standardize periorbital steroid injections in treating TAO.

关 键 词：GRAVES眼病 糖皮质激素类 曲安奈德 规范 甲状腺相关眼病 眶周注射 

分 类 号：R581[医药卫生—内分泌] R771.3[医药卫生—内科学]